Compare Quest Diagnostics Inc (DGX) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Sony Group Corp — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Sony Group Corp trades at $20.74 (market cap $122.79B). The key difference: Sony Group Corp is far larger — about 5.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | SONY | |
|---|---|---|
Market Cap | $22.80B | $122.79B |
Sector | Health | Technology |
52-Week High | $216.02 | $30.26 |
52-Week Low | $166.42 | $19.32 |
Enterprise Value | $28.82B | $119.28B |
Dividend Yield | 1.67% | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Sony trades at $20.68, down 0.82% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong operating cash flow of $2.32 trillion for 2025 and maintains solid valuation metrics including a P/E of 19.51. Recent news highlights Sony's strategic shift to digital-only PlayStation games by 2028 and conditional approval for a U.S. stablecoin bank.
Outlook remains mixed with analyst consensus strongly bullish (69% buy ratings) but near-term earnings volatility. Key opportunities include digital transformation and financial services expansion, while risks involve execution of digital strategy and projected net income decline to -$326.9 billion for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
